Cabozantinib in progressive medullary thyroid cancer

Journal of Clinical Oncology

Volumn 31, Issue 29, 2013, Pages 3639-3646

  Elisei, Rossella ^a   Schlumberger, Martin J ^c   Müller, Stefan P ^d   Schöffski, Patrick ^f   Brose, Marcia S ^g   Shah, Manisha H ^h   Licitra, Lisa ^b   Jarzab, Barbara ⁱ   Medvedev, Viktor ^j   Kreissl, Michael C ^e   Niederle, Bruno ^k   Cohen, Ezra E W ^l   Wirth, Lori J ^m   Ali, Haythem ⁿ   Hessel, Colin ^o   Yaron, Yifah ^o   Ball, Douglas ^p   Nelkin, Barry ^p   Sherman, Steven I ^q  

^a UNIVERSITY OF PISA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^f UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

ⁱ INSTITUTE OF ONCOLOGY   (Poland)

^j INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^k MEDICAL UNIVERSITY OF VIENNA   (Austria)

^l UNIVERSITY OF CHICAGO   (United States)

^m MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁿ HENRY FORD HEALTH SYSTEM   (United States)

^o EXELIXIS INC   (United States)

^p JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CABOZANTINIB; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; PLACEBO; ANILIDE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ABDOMINAL ABSCESS; ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ARTERY THROMBOSIS; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BLEEDING; BONE NECROSIS; CANCER SURVIVAL; CARDIOPULMONARY INSUFFICIENCY; CLINICAL OUTCOME; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPEPSIA; DYSPHAGIA; DYSPHONIA; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; FISTULA; GENE MUTATION; GLOSSODYNIA; HAIR COLOR; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERTENSION; HYPOCALCEMIA; INSOMNIA; KAPLAN MEIER METHOD; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MOUTH PAIN; MUCOSA INFLAMMATION; MULTIPLE ORGAN FAILURE; MUSCLE SPASM; NAUSEA; ONCOGENE RET; OROPHARYNX PAIN; OVERALL SURVIVAL; PELVIS ABSCESS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY FAILURE; SEPSIS; STOMATITIS; SUDDEN DEATH; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; VOMITING; WEIGHT REDUCTION; WOUND COMPLICATION; XEROSTOMIA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; THYROID NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANILIDES; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRIDINES; THYROID NEOPLASMS;

EID: 84890571003     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.48.4659     Document Type: Article

References (37)

1. Schlumberger M, Carlomagno F, Baudin E, et al: New therapeutic approaches to treat medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab 4:22-32, 2008
2. Enewold L, Zhu K, Ron E, et al: Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 18:784-791, 2009
3. Lodish MB, Stratakis CA: RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Expert Rev Anticancer Ther 8:625-632, 2008
4. Fialkowski EA, Moley JF: Current approaches to medullary thyroid carcinoma, sporadic and familial. J Surg Oncol 94:737-747, 2006
5. Kouvaraki MA, Shapiro SE, Perrier ND, et al: RET proto-oncogene: A review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid 15:531-544, 2005
6. Dvorakova S, Vaclavikova E, Sykorova V, et al: Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 284:21-27, 2008
7. Elisei R, Cosci B, Romei C, et al: Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: A 10-year follow-up study. J Clin Endocrinol Metab 93:682-687, 2008
8. Moura MM, Cavaco BM, Pinto AE, et al: Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 100:1777-1783, 2009
9. Alberti L, Carniti C, Miranda C, et al: RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol 195:168-186, 2003
10. Schilling T, Bürck J, Sinn HP, et al: Prognostic value of codon 918 (ATG3ACG) RET protooncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer 95:62-66, 2001
11. Trovato M, Villari D, Bartolone L, et al: Expression of the hepatocyte growth factor and c-met in normal thyroid, non-neoplastic, and neoplastic nodules. Thyroid 8:125-131, 1998
12. Capp C, Wajner SM, Siqueira DR, et al: Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid 20:863-871, 2010
13. Papotti M, Olivero M, Volante M, et al: Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocr Pathol 11:19-30, 2000
14. Soh EY, Duh QY, Sobhi SA, et al: Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 82:3741-3747, 1997
15. Cassinelli G, Favini E, Degl'Innocenti D, et al: RET/PTC1-driven neoplastic transformation and proinvasive phenotype of human thyrocytes involve Met induction and beta-catenin nuclear translocation. Neoplasia 11:10-21, 2009
16. Peixoto Callejo I, Américo Brito J, Zagalo CM, et al: Medullary thyroid carcinoma: Multivariate analysis of prognostic factors influencing survival. Clin Transl Oncol 8:435-443, 2006
17. Machens A, Schneyer U, Holzhausen HJ, et al: Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 90:2029-2034, 2005
18. Barbet J, Campion L, Kraeber-Bodéré F, et al: Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90:6077-6084, 2005
19. Machens A, Ukkat J, Hauptmann S, et al: Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: A multivariate analysis. Arch Surg 142:289-293, 2009
20. Laure Giraudet A, Al Ghulzan A, Aupérin A, et al: Progression of medullary thyroid carcinoma: Assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 158:239-246, 2008
21. Busnardo B, Girelli ME, Simioni N, et al: Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 53:278-285, 1984
22. Elisei R, Bottici V, Luchetti F, et al: Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: Experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 89:163-168, 2004
23. Orlandi F, Caraci P, Mussa A, et al: Treatment of medullary thyroid carcinoma: An update. Endocr Relat Cancer 8:135-147, 2001
24. Wells SA Jr, Robinson BG, Gagel RF, et al: Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: A randomized, double-blind phase III trial. J Clin Oncol 30:134-141, 2012
25. Yakes FM, Chen J, Tan J, et al: Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 10:2298-2308, 2011
26. Kurzrock R, Sherman SI, Ball DW, et al: Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29:2660-2666, 2011
27. Schöffski P, Elisei R, Müller S, et al: An international, double-blind, randomized, placebocontrolled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol 30:358s, 2012 (suppl; abstr 5508)
28. Nagilla M, Brown RL, Cohen EE: Cabozantinib for the treatment of advanced medullary thyroid cancer. Adv Ther 29:925-934, 2012
29. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
30. American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al: Medullary thyroid cancer: Management guidelines of the American Thyroid Association. Thyroid 19:565-612, 2009
31. Lam ET, Ringel MD, Kloos RT, et al: Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 28:2323-2330, 2010
32. Cohen EE, Rosen LS, Vokes EE, et al: Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 26:4708-4713, 2008
33. Schlumberger MJ, Elisei R, Bastholt L, et al: Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794-3801, 2009
34. Akeno-Stuart N, Croyle M, Knauf JA, et al: The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res 67:6956-6964, 2007
35. Kamba T, McDonald DM: Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788-1795, 2007
36. Kappers MH, van Esch JH, Smedts FM, et al: Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J Clin Endocrinol Metab 96:3087-3094, 2011
37. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, et al: A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92:3466-3469, 2007